Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer ...

Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key ...

Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...

Harrison noted that responses were observed across calreticulin mutation types and among patients with additional mutations, with minimal toxicity reported to date. She concluded by describing ...

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Christina Poh confirmed that the disconnect between provider and patient experiences of shared decision-making resonates strongly with what she observes in clinical practice, noting that while care ...

Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

In a recent podcast, Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, offered a candid account ...

Learn how daratumumab exposure vs refractoriness guides second-line myeloma therapy, and what MajesTEC trials suggest for BCMA bispecifics. In 'Refractory vs. Exposed: How Anti-CD38 Status Shapes ...